1291 related articles for article (PubMed ID: 17970879)
1. The efficacy of bismuth containing quadruple therapy as a first-line treatment option for Helicobacter pylori.
Uygun A; Kadayifci A; Safali M; Ilgan S; Bagci S
J Dig Dis; 2007 Nov; 8(4):211-5. PubMed ID: 17970879
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the efficacy of 1-day high-dose quadruple therapy versus 7-day triple therapy for treatment of Helicobacter pylori infection.
Zheng Q; Pan Y; Zhang L; Xiao SD
Chin J Dig Dis; 2005; 6(4):202-5. PubMed ID: 16246231
[TBL] [Abstract][Full Text] [Related]
3. The impact of primary antibiotic resistance on the efficacy of ranitidine bismuth citrate- vs. omeprazole-based one-week triple therapies in H. pylori eradication--a randomised controlled trial.
Bago J; Halle ZB; Strinić D; Kućisec N; Jandrić D; Bevanda M; Tomić M; Bilić A
Wien Klin Wochenschr; 2002 Jun; 114(12):448-53. PubMed ID: 12422579
[TBL] [Abstract][Full Text] [Related]
4. Randomized comparison of ranitidine bismuth citrate-based triple therapies for Helicobacter pylori.
Laine L; Estrada R; Trujillo M; Emami S
Am J Gastroenterol; 1997 Dec; 92(12):2213-5. PubMed ID: 9399755
[TBL] [Abstract][Full Text] [Related]
5. Comparison of sequential and standard triple-drug regimen for Helicobacter pylori eradication: a 14-day, open-label, randomized, prospective, parallel-arm study in adult patients with nonulcer dyspepsia.
Uygun A; Kadayifci A; Yesilova Z; Safali M; Ilgan S; Karaeren N
Clin Ther; 2008 Mar; 30(3):528-34. PubMed ID: 18405790
[TBL] [Abstract][Full Text] [Related]
6. Bismuth subsalicylate instead of metronidazole with lansoprazole and clarithromycin for Helicobacter pylori infection: a randomized trial.
Chey WD; Fisher L; Elta GH; Barnett JL; Nostrant T; DelValle J; Hasler WL; Scheiman JM
Am J Gastroenterol; 1997 Sep; 92(9):1483-6. PubMed ID: 9317068
[TBL] [Abstract][Full Text] [Related]
7. Ranitidine bismuth citrate-based triple therapies as a second-line therapy for Helicobacter pylori in Turkish patients.
Köksal AS; Parlak E; Filik L; Yolcu OF; Odemiş B; Ulker A; Saşmaz N; Ozden A; Sahin B
J Gastroenterol Hepatol; 2005 Apr; 20(4):637-42. PubMed ID: 15836716
[TBL] [Abstract][Full Text] [Related]
8. Lafutidine versus lansoprazole in combination with clarithromycin and amoxicillin for one versus two weeks for Helicobacter pylori eradication in Korea.
Kim N; Park SH; Seo GS; Lee SW; Kim JW; Lee KJ; Shin WC; Kim TN; Park MI; Park JJ; Hong SJ; Shim KN; Kim SW; Shin YW; Chang YW; Chun HJ; Lee OJ; Jeon WJ; Park CG; Cho CM; Park CH; Won SY; Lee GH; Park KS; Shin JE; Kim HU; Park JY; Chae HS; Song GA; Kim JG; Yoon BC; Seol S; Jung HC; Chung IS
Helicobacter; 2008 Dec; 13(6):542-9. PubMed ID: 19166420
[TBL] [Abstract][Full Text] [Related]
9. High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication.
Sun Q; Liang X; Zheng Q; Liu W; Xiao S; Gu W; Lu H
Helicobacter; 2010 Jun; 15(3):233-8. PubMed ID: 20557366
[TBL] [Abstract][Full Text] [Related]
10. One-day quadruple therapy compared with 7-day triple therapy for Helicobacter pylori infection.
Lara LF; Cisneros G; Gurney M; Van Ness M; Jarjoura D; Moauro B; Polen A; Rutecki G; Whittier F
Arch Intern Med; 2003 Sep; 163(17):2079-84. PubMed ID: 14504122
[TBL] [Abstract][Full Text] [Related]
11. Anti-Helicobacter pylori treatment in bleeding ulcers: randomized controlled trial comparing 2-day versus 7-day bismuth quadruple therapy.
Kung NN; Sung JJ; Yuen NW; Ng PW; Wong KC; Chung EC; Lim BH; Choi CH; Li TH; Ma HC; Kwok SP
Am J Gastroenterol; 1997 Mar; 92(3):438-41. PubMed ID: 9068464
[TBL] [Abstract][Full Text] [Related]
12. First-line eradication therapy for Helicobacter pylori in primary health care based on antibiotic resistance: results of three eradication regimens.
Koivisto TT; Rautelin HI; Voutilainen ME; Heikkinen MT; Koskenpato JP; Färkkilä MA
Aliment Pharmacol Ther; 2005 Mar; 21(6):773-82. PubMed ID: 15771764
[TBL] [Abstract][Full Text] [Related]
13. Second-line Helicobacter pylori eradication: a randomized comparison of 1-week or 2-week bismuth-containing quadruple therapy.
Chung JW; Lee JH; Jung HY; Yun SC; Oh TH; Choi KD; Song HJ; Lee GH; Kim JH
Helicobacter; 2011 Aug; 16(4):289-94. PubMed ID: 21762268
[TBL] [Abstract][Full Text] [Related]
14. Eradication rates of helicobacter pylori infection with second-line treatment: non-ulcer dyspepsia compared to peptic ulcer disease.
Chung SJ; Lee DH; Kim N; Jung SH; Kim JW; Hwang JH; Park YS; Lee KH; Jung HC; Song IS
Hepatogastroenterology; 2007 Jun; 54(76):1293-6. PubMed ID: 17629092
[TBL] [Abstract][Full Text] [Related]
15. One-week triple therapy with ranitidine bismuth citrate, clarithromycin and metronidazole versus two-week dual therapy with ranitidine bismuth citrate and clarithromycin for Helicobacter pylori infection: a randomized, clinical trial.
van der Wouden EJ; Thijs JC; van Zwet AA; Kooy A; Kleibeuker JH
Am J Gastroenterol; 1998 Aug; 93(8):1228-31. PubMed ID: 9707042
[TBL] [Abstract][Full Text] [Related]
16. Twice-a-day bismuth-containing quadruple therapy for Helicobacter pylori eradication: a randomized trial of 10 and 14 days.
Dore MP; Farina V; Cuccu M; Mameli L; Massarelli G; Graham DY
Helicobacter; 2011 Aug; 16(4):295-300. PubMed ID: 21762269
[TBL] [Abstract][Full Text] [Related]
17. Comparison of three different second-line quadruple therapies including bismuth subcitrate in Turkish patients with non-ulcer dyspepsia who failed to eradicate Helicobacter pylori with a 14-day standard first-line therapy.
Uygun A; Ozel AM; Yildiz O; Aslan M; Yesilova Z; Erdil A; Bagci S; Gunhan O
J Gastroenterol Hepatol; 2008 Jan; 23(1):42-5. PubMed ID: 17559359
[TBL] [Abstract][Full Text] [Related]
18. The efficacy of ranitidine bismuth citrate, amoxicillin and doxycycline or tetracycline regimens as a first line treatment for Helicobacter pylori eradication.
Akyildiz M; Akay S; Musoglu A; Tuncyurek M; Aydin A
Eur J Intern Med; 2009 Jan; 20(1):53-7. PubMed ID: 19237093
[TBL] [Abstract][Full Text] [Related]
19. Ten-day sequential versus triple therapy for Helicobacter pylori eradication: a prospective, open-label, randomized trial.
Chung JW; Jung YK; Kim YJ; Kwon KA; Kim JH; Lee JJ; Lee SM; Hahm KB; Lee SM; Jeong JY; Yun SC
J Gastroenterol Hepatol; 2012 Nov; 27(11):1675-80. PubMed ID: 22849546
[TBL] [Abstract][Full Text] [Related]
20. Cumulative H. pylori eradication rates in clinical practice by adopting first and second-line regimens proposed by the Maastricht III consensus and a third-line empirical regimen.
Rokkas T; Sechopoulos P; Robotis I; Margantinis G; Pistiolas D
Am J Gastroenterol; 2009 Jan; 104(1):21-5. PubMed ID: 19098844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
